MarcVervloet Radboud University Medical center, The Netherlands

Upload Picture

https://storage.unitedwebnetwork.com/files/1099/d173cffe32946658915e54fae67d3afe.jpg

First Name

Marc

Last Name

Vervloet

Institution

Country.

Time	Session

9:45 a.m. 11:15 a.m.	CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered ArvindBagga Chair arvindbagga@hotmail.comIndia UttaraDas Chair uttaradas806@gmail.comIndia What Should a Clinician Know About CKD-MBD in 2025? HanneJoergensen Speaker hsjorgensen@clin.au.dkAarhus UniversityDenmark CKD-MBD in Children and Young Adults: What's the Difference? SukanyaGovindan Speaker Mehta Children's Hospitals and MGM healthcare, Chennai, India Progress in CKD-driven Vascular Calcification: From Bench to Bedside MarcVervloet Speaker Radboud University Medical center, The Netherlands How to Use Serum Biomarkers for Optimal Management of CKD-MBD SandroMazzaferro Speaker Sapienza University of Rome, ItalyItaly Q&A Gulmohar Hall 302

Time

Session

9:45 a.m.

11:15 a.m.

CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered

ArvindBagga Chair arvindbagga@hotmail.comIndia

UttaraDas Chair uttaradas806@gmail.comIndia

What Should a Clinician Know About CKD-MBD in 2025?

HanneJoergensen Speaker hsjorgensen@clin.au.dkAarhus UniversityDenmark
CKD-MBD in Children and Young Adults: What's the Difference?

SukanyaGovindan Speaker Mehta Children's Hospitals and MGM healthcare, Chennai, India
Progress in CKD-driven Vascular Calcification: From Bench to Bedside

MarcVervloet Speaker Radboud University Medical center, The Netherlands
How to Use Serum Biomarkers for Optimal Management of CKD-MBD

SandroMazzaferro Speaker Sapienza University of Rome, ItalyItaly
Q&A

Gulmohar Hall 302